Avid Bioservices Inc (CDMO)

[biopharm]

How does Michael Chisamore with Merck get involved with Biothera and Oncologie Laura Benjamin now fully tied into Biothera.... all the puzzle pieces will surface and PS Targeting is at the heart and center of it all. Ex Eli Lilly employees that were let go early retirement we're targeted and this gets bigger and all the puzzle pieces place John Springs Stafford in the mix to lie to shareholders and current Avid Bioservices BOD are silenced for now

How big is PS Targeting? Big enough for some to risk paying fines

____

The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.

“Cancer is not one disease but rather more than 200 diseases, all of which have different causes and treatments,” said Richard Gaynor, M.D., senior vice president, product development and medical affairs, Lilly Oncology. “Therefore research into combinations of immune-based therapies with other agents that could address these different tumor types is important. This collaboration between Lilly and Merck represents each company’s strong commitment to patients fighting these devastating diseases.”

https://www.mrknewsroom.com/news-release/oncology-newsroom/lilly-merck-enter-collaboration-agreement-research-immuno-oncology-co

_______

Jeremy Graff ex Eli Lilly working with Laura Benjamin and they all require PS Targeting rights and knowledge

_________


https://www.biothera.com/biothera-pharmaceuticals-announces-management-changes/


Since joining Biothera Pharmaceuticals in 2014 as Chief Scientific Officer, Dr. Graff has led research demonstrating the synergy between Imprime PGG and immune checkpoint inhibitors—the focus of the Company’s clinical development plan. Under Dr. Graff’s leadership, Biothera has refined its understanding of the anti-cancer therapeutic activity of Imprime PGG and further validated its biomarker-driven, patient selection strategies. Before joining Biothera, Dr. Graff held numerous leadership positions at Eli Lilly and Company, culminating in his role in developing the Lilly Translational Oncology effort.